Pharmacotherapy

• 

  Publication Venue For

  • Early versus delayed initiation of cytomegalovirus prophylaxis after liver transplant..  42:634-640. 2022
  • Factors contributing to improved adherence rates following a clinical pharmacist intervention.  32:E128-E128. 2012
  • Testosterone supplementation for hypoactive sexual desire disorder in women..  32:38-53. 2012
  • Current options in antifungal pharmacotherapy..  28:614-645. 2008
  • Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting..  28:376-392. 2008
  • Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia..  27:970-979. 2007
  • Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy..  27:691-696. 2007
  • Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections..  27:227-249. 2007
  • Atypical antipsychotics and pituitary tumors: a pharmacovigilance study..  26:748-758. 2006
  • Pharmacotherapy for human immunodeficiency virus-associated nephropathy..  25:1761-1772. 2005
  • Outcomes from an outpatient smoking-cessation clinic..  25:279-288. 2005
  • Key references in infectious diseases pharmacotherapy..  24:1586-1593. 2004
  • Pharmacovigilance in the 21st century: new systematic tools for an old problem..  24:1099-1104. 2004
  • Chronic Obstructive Pulmonary Disease.  24. 2004
  • Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy..  24:488-494. 2004
  • Evaluating the impact of pharmacists in mental health: a systematic review..  23:1634-1644. 2003
  • New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance..  23:1316-1321. 2003
  • Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports..  23:1123-1130. 2003
  • Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia..  23:1S-2S. 2003
  • Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy..  23:15S-19S. 2003
  • Statin-associated memory loss: analysis of 60 case reports and review of the literature..  23:871-880. 2003
  • Risperidone-associated diabetes mellitus: a pharmacovigilance study..  23:735-744. 2003
  • A 24-hour comparison of serum growth hormone concentrations in patients with heart failure versus healthy controls..  23:147-152. 2003
  • Patient detection of a drug dispensing error by use of physician-provided drug samples.  22:1642-1643. 2002
  • Patient detection of a drug dispensing error by use of physician-provided drug samples..  22:1642-1643. 2002
  • Practitioner acceptance of the dofetilide risk-management program..  22:1041-1046. 2002
  • Olanzapine-associated diabetes mellitus..  22:841-852. 2002
  • Asthma exacerbation after administration of nicotine nasal spray for smoking cessation..  22:779-782. 2002
  • Torsades de pointes associated with fluoroquinolones - Reply.  22:668-672. 2002
  • Torsades de pointes associated with fluoroquinolones..  22:663-668. 2002
  • Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin..  21:1468-1472. 2001
  • Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature..  21:1448-1454. 2001
  • Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program..  21:636-641. 2001
  • Antifungal pharmacodynamics: review of the literature and clinical applications..  20:1335-1355. 2000
  • A predictive model for neutropenia associated with cancer chemotherapy..  20:104S-111S. 2000
  • Interactive discussion on chemotherapy-related adverse events..  20:121S-125S. 2000
  • Inappropriate drug use among community-dwelling elderly..  20:575-582. 2000
  • Lamotrigine-induced blepharospasm..  19:877-880. 1999
  • Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring..  19:383-387. 1999
  • Management of patients with vertebral compression fractures..  19:21S-24S. 1999
  • The cost-effectiveness of a clinical pharmacist intervention among elderly outpatients.  18:327-332. 1998
  • Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature..  18:1053-1061. 1998
  • The cost-effectiveness of a clinical pharmacist intervention among elderly outpatients..  18:327-332. 1998
  • A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy..  17:836-840. 1997
  • Predictors of nutritional supplement use by the elderly..  16:715-720. 1996
  • Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin..  16:584-592. 1996
  • Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers..  14:509-513. 1994
  • Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications..  12:161-173. 1992
  • Colony-stimulating factors: clinical applications..  12:20S-31S. 1992
  • Relationship between serum quinidine concentration and quinidine dosage..  12:189-194. 1992
  • Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application..  8:35-46. 1988
  • Alprazolam in bipolar-I depressions..  4:40-42. 1984
  • The influence of acid suppressants on oral and fecal microbiomes in critically ill patients 2015
  • The prevalence of HIV testing in pregnant women. 2014
  • Risk factors for unfavorable short-term treatment outcome in patients with invasive Pseudomonas aeruginosa infection 2013
  • Development and pharmacokinetic characterization of new delayed pulsatile-release ondansetron formulation. 2012
  • Treatment options for invasive fungal infections. 2006
  • Clinically serious drug-disease interactions in the elderly: opinion of a consensus panel. 2005
  • Potential impact of the modification of diet in renal disease (MDRD) equation on antibiotic dosing. 2005
  • Predictors of excess dosing of injectable antithrombotics in patients with non-ST-segment elevation acute coronary syndromes. 2005
  • Planning and implementation of a multimodal medication error tracking, reporting and prevention program. 2004
  • Cost-avoidance associated with infectious diseases clinical research. 2003
  • Patterns of anti-osteoporotic drug use among older community dwelling west Texans and associated factors. 2002